A Pan-Cancer Analysis of SLC12A5 Reveals Its Correlations with Tumor Immunity

• Published in: Disease markers Vol. 2021; pp. 1 - 11
• Main Authors: Jiang, Yi, Liao, Hong-li, Chen, Li-ya
• Format: Journal Article
• Language: English
• Published: United States Hindawi 2021; John Wiley & Sons, Inc
• Subjects: Biomarkers; Biomarkers, Tumor - genetics; Cancer; Disease Progression; DNA Mismatch Repair; Gene expression; Gene Expression Profiling - methods; Gene Expression Regulation, Neoplastic; Humans; Immunity; Immunology; Immunotherapy; Lymphocytes; Medical prognosis; Microsatellite Instability; Mismatch repair; Mutation; Neoplasm Staging; Neoplasms - genetics; Neoplasms - pathology; Prognosis; Sequence Analysis, RNA; Survival; Survival Analysis; Symporters - genetics; Tumors; Up-Regulation
• ISSN: 0278-0240; 1875-8630; 1875-8630
• DOI: 10.1155/2021/3062606

Background. Solute carrier family 12 member 5 (SLC12A5) has been reported to play an oncogenic role in certain malignancies. Its prognostic roles and immune mechanisms of action in human cancers, however, remain largely unknown. Methods. Data derived from TCGA, GEPIA, and TIMER databases were utilized to delve into the expressing patterns, prognostic values, clinical significances, and tumor immunity of SLC12A5 in tumors. Additionally, the association of SLC12A5 expressions with tumor mutation burden (TMB), methyltransferases, and mismatch repairs (MMRs) was also analyzed. Results. Herein, we observed that SLC12A5 was significantly overexpressed in various malignancies, and SLC12A5 levels correlated with overall survival, disease-specific survival, and tumor stage of certain cancers. Furthermore, we noticed that SLC12A5 was distinctly associated with methyltransferases, mismatch repair proteins, TMB, and MSI in human cancers. Conclusions. SLC12A5 may act as a potential prognostic and immunological biomarker and therapeutic target for human cancers.